Monitoring Selected National HIV Prevention and Care Objectives By Using HIV Surveillance Data United States and 6 Dependent Areas, 2020: Appendix

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Stage of disease at time of HIV diagnosis is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Area without laws: New Jersey. Area with incomplete lab reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.
^aFirst positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^bIncludes persons with no CD4 information.
^cData should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence at time of diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. A VL test result of < 200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2020. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Area without laws: New Jersey. Area with incomplete lab reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.
^aData should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2020 (i.e., most recent known address). Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the Centers for Disease Control and Prevention. Area without laws: New Jersey. Area with incomplete lab reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.
^aPerformed ≥3 months apart during 2020.
^bA VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2020.
^cData should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.
^dData should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2020.

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2020 (i.e., most recent known address). Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results during 2020. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the Centers for Disease Control and Prevention. Area without laws: New Jersey. Area with incomplete lab reporting: Pennsylvania (excluding Philadelphia) and Puerto Rico.
^aData should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.
^bData should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2020.

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration; NHSS, National HIV Surveillance System [footnotes only].
^aEstimated by using data from IQVIA pharmacy database reported through September 2021 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; therefore, values may not sum to column total.
^bEstimated using 2018 data from National HIV Surveillance System (NHSS), National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey (ACS). Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. The 2018 denominators were used for 2020 PrEP coverage data.
^cPrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
^dData value <40 was not reported due to unreliability.